Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

185
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
185
Cancer Survival Analysis01:21

Cancer Survival Analysis

463
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
463

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of low-dose immune checkpoint inhibitors in low- and middle-income countries: a national survey of oncologists and hematologists in Mexico.

Ecancermedicalscience·2026
Same author

Volume-Staged Stereotactic Radiosurgery in Pediatric Patients With Large Brain Arteriovenous Malformations: An International, Multicenter Study.

Neurosurgery·2026
Same author

Paving the Way for a Career in High Value Care: A Roadmap for Future Clinician Leaders.

Journal of general internal medicine·2026
Same author

Efficacy and safety profile of volume-staged stereotactic radiosurgery for ruptured, large pediatric arteriovenous malformations: a multicenter cohort analysis.

Journal of neurosurgery. Pediatrics·2026
Same author

Characteristics of Crowdfunding Campaigns for Proton Therapy.

International journal of radiation oncology, biology, physics·2026
Same author

Paid Sick Leave, Care Delays, and Mortality Risk in Working Cancer Survivors.

JCO oncology practice·2026

Related Experiment Video

Updated: Sep 21, 2025

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
08:56

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Published on: May 17, 2018

9.3K

Financial Toxicity as an End Point in Prospective Clinical Trials Involving Radiation Therapy.

Rahul N Prasad1, Trevor J Royce2,3, Fumiko Chino4

  • 1Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.

Advances in Radiation Oncology
|May 27, 2022
PubMed
Summary

Financial toxicity (FT) is a significant concern for cancer patients undergoing radiation therapy (RT). Despite increasing awareness, FT endpoints are rarely included in RT clinical trials, hindering effective management.

More Related Videos

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis
07:08

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis

Published on: August 31, 2022

1.8K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K

Related Experiment Videos

Last Updated: Sep 21, 2025

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue
08:56

Evaluating the Role of Mitochondrial Function in Cancer-related Fatigue

Published on: May 17, 2018

9.3K
Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis
07:08

Establishment of a Robust and Reproducible Model of Radiation-Induced Skin and Muscle Fibrosis

Published on: August 31, 2022

1.8K
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.4K

Area of Science:

  • Oncology
  • Health Economics
  • Clinical Research Methodology

Background:

  • Patients with cancer face elevated risks of financial toxicity (FT).
  • Radiation therapy (RT) can be particularly burdensome due to prolonged treatment schedules.
  • Limited research exists on FT in RT patients and its inclusion in clinical trials.

Purpose of the Study:

  • To assess the frequency of financial toxicity (FT) endpoints in prospective clinical trials involving radiation therapy (RT).
  • To analyze trends in the inclusion of FT endpoints in RT trials over time.
  • To evaluate how FT is measured when included in RT clinical trials.

Main Methods:

  • A comprehensive query of ClinicalTrials.gov identified RT cancer studies from 2001-2020.
  • Studies reporting primary, secondary, or exploratory FT endpoints were selected.
  • Data on study characteristics and FT measures were collected and analyzed using descriptive statistics and chi-squared tests.

Main Results:

  • Out of 10,550 RT studies, only 88 (0.8%) reported FT endpoints.
  • FT endpoints were predominantly secondary (78%) and rarely standalone (22%).
  • Inclusion of FT endpoints increased significantly from 0.1% (2001-2005) to 1.5% (2016-2020), P < .0001.

Conclusions:

  • Financial toxicity (FT) is underrepresented as an endpoint in radiation therapy (RT) clinical trials.
  • Current measurements of FT are often integrated into broader quality of life questionnaires, lacking validation.
  • Future prospective RT trials should prioritize the inclusion of robust FT endpoints to better understand and mitigate patient financial burden.